Lack of association between LincRNA-Pou3f gene expression and clinicopathological features in gastric cancer tissue

Emerging evidence supports the effective therapeutics for advanced or metastatic gastric cancers which have undergone little progress. Multiple pathophysiological process of lincRNA-POU3F3 and the critical roles in gastric cancer are not clearly defined. The aim of this study was to evaluate the expression of LincRNA-POU3F3 in gastric cancer compared to the adjacent healthy tissue to gain further knowledge about the aberrantly expressed value of selected lincRNA. The RNA was extracted from 42 gastric tumor tissue samples and paired adjacent normal tissues from the patients included in the present study. The expression of LincRNA-POU3F3 was assessed using the Real-time polymerase chain reaction. B2M was used as an internal control. The 2(-Delta Delta Cq) method was used to determine the expression fold changes (tumor vs. adjacent normal tissue). The extent of the LincRNA-POU3F3 gene expression was compared among 42 tumor tissues and adjacent normal tissues (the mean age of the study group was 60.32 +/- 14.185 years). The level of the LincRNA-POU3F3 gene expression revealed no statistically significant difference between the tumor and adjacent normal tissues (P = 0.065). In order to further evaluate the role of LincRNA-POU3F3 in gastric cancer, the associations between the transcript levels of the gene and several clinicopathological features demonstrated no significant difference between the stages I, III and IV (P = 0.84), tumor grade groups (P = 0.44), Helicobacter pylori (H. pylori) infection (P = 0.06) and tumor size (P = 0.71). Taken together, our results demonstrated that the expression of LincRNA-POU3F3 at the transcriptional level had no significant difference in gastric cancer tissue samples. Due to this, it is not a potential target for diagnostic/therapeutic purposes.